Pharmaceuticals
GenScript Receives FDA Emergency Use Authorization for World's First SARS-CoV-2 Neutralizing Antibody Detection Kit
PISCATAWAY, N.J., Nov. 9, 2020 /PRNewswire/ -- GenScript USA Inc., the world's
leading research reagent provider, announced today that the U.S. Food and Drug
Administration (FDA) has grantedEmergency Use Authorization (EUA)
2020-11-09 20:30
3843
TaiGen Partners with GPCR to develop Burixafor & Taigexyn(R)
TAIPEI, Nov. 9, 2020 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announced today that they have signed an exclusive agreement with GPCR Therapeutics, Inc. ("GPCR"), a leading Korean biotechnology company, for the continued development of Burixafor worldwide and the commercial...
2020-11-09 18:22
1798
Covid-19 Vaccination Plan: Badan POM Set to Ensure and Safeguard the safety, efficacy, and quality of Covid-19 vaccine
* Prudent approach and usability are among the top priorities * Efforts are underway to provide the best efficacy for public at large JAKARTA, Indonesia, Nov. 9, 2020 /PRNewswire/ -- In a bid to support the government's plan to develop Covid-19 vaccine inIndonesia, the National Drug and Food ...
2020-11-09 17:25
2398
Inmagene Biopharmaceuticals closed $21 million Series B financing, making the total raised to date over $40 million
SHANGHAI, Nov. 8, 2020 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), announced today that it had closed a$21 million Series B financing, led by Vertex Ventures China, and co-invested by Panacea Venture, Kunlun Capital, SCVC and a few other investors. The Series B financing will b...
2020-11-09 08:00
2203
Merck and Transcenta Collaborate to Advance Continuous Biomanufacturing, Make the 'Facility of the Future' a Reality
* Companies to co-develop a first-of-its-kind, single-use flow-through polishing system for GMP operation * Merck's continuous processing expertise to accelerate Transcenta's development, implementation of continuous bioprocessing platform * Collaboration expected to accelerate affordable ac...
2020-11-08 17:14
3814
Merck to Collaborate with Donghao Lansheng to Pilot New Import Policy in China
* Merck is first international company to pilot the new custom clearance
process SHANGHAI, Nov. 8, 2020 /PRNewswire/ -- On November 6, Merck
2020-11-08 17:08
2751
CARE GA Receives Study May Proceed Letter from US FDA to Initiate Phase II Clinical Trial of Senhwa's Silmitasertib in COVID-19 Patients
TAIPEI and SAN DIEGO, Nov. 6, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced its clinical partner- Center for Advanced Research an...
2020-11-06 22:00
3524
Daewoong Pharmaceutical Announces Publication of Novel P-CAB Fexuprazan Phase 1 Bridging Study
SEOUL, South Korea, Nov. 6, 2020 /PRNewswire/ -- On October 27, the bridging study results on Fexuprazan, developed by the Korean pharmaceutical company, Daewoong Pharmaceutical (Daewoong; CEOSengho Jeon), was published in the SCI medical journal Alimentary Pharmacology and Therapeutics (AP&T). F...
2020-11-06 22:00
2647
XJTLU launches new Academy of Pharmacy
SUZHOU, China, Nov. 6, 2020 /PRNewswire/ -- On 11 November 2020, Xi'an Jiaotong- Liverpool University will launch its new XJTLU Wisdom Lake Academy of Pharmacy. "The biopharmaceutical industry is one of the fastest-growing sectors worldwide," says DrYimin Ding, Vice President of XJTLU. "It is a...
2020-11-06 20:00
2484
New Drug for Gastrointestinal Stromal Tumours (GIST) to be Launched in Australia, New Zealand and South East Asia Following Distribution Agreement
Key Highlights: * Specialised Therapeutics Asia (STA) to make QINLOCK® (ripretinib) available to appropriate patients inAustralia, New Zealand, Singapore, Malaysia and Brunei following exclusive distribution agreement * QINLOCK is already approved by the Therapeutics Good Administration (TGA)...
2020-11-06 05:30
4265
Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioural therapy
BAGSVÆRD, Denmark, Nov. 6, 2020 /PRNewswire/ -- Results of a phase 3a trial showed that investigational drug semaglutide 2.4 mg once-weekly subcutaneous as an adjunct to intensive behavioural therapy (IBT) demonstrated significantly more body weight loss compared to placebo plus IBT.[i] The STEP ...
2020-11-06 01:50
2504
Porton Biologics Launched Gene and Cell Therapy CDMO Platform to Rank Among the Top of Pharma Solutions Platforms
SUZHOU, China, Nov. 5, 2020 /PRNewswire/ -- On November 1, the Opening Ceremony of Porton Biologics Gene and Cell Therapy CDMO Platform was held in Suzhou,China . As Porton Biologics is committed to building an end-to-end gene and cell therapy CDMO service platform, the phase I construction of th...
2020-11-05 15:35
5333
TCM Lianhua Qingwen's Access to Russian Market Marks Its Global Expansion
SHIJIAZHUANG, China, Nov. 5, 2020 /PRNewswire/ -- Yiling Pharmaceutical (002603.SZ) discloses that it has received the Certificate of Registration for Dietary Supplements approved and issued by the authorized agency of Eurasian Economic Union, which indicates that the company's patent drug Lianhu...
2020-11-05 14:08
8070
Asieris Announces Approval of its Phase III Trial of a Novel Single Oral Agent as First-line Treatment for Non-Muscle Invasive Bladder Cancer (NMIBC)
SHANGHAI, Nov. 5, 2020 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris), a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases, recently announced that the Center for Drug Evaluation (CDE) ...
2020-11-05 13:59
1384
Innovent and Lilly Jointly Announce Results of Seven Clinical Studies of TYVYT® (sintilimab injection) to Be Presented at the ESMO ASIA Congress 2020
SAN FRANCISCO and SUZHOU, China, Nov. 5, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for treatment of oncology, metabolic, autoimmune and other major disease...
2020-11-05 08:00
6020
U.S. FDA Accepts Ortho's Emergency Use Notification for VITROS(R) SARS-CoV-2 Antigen Test--Capable of Accurate Mass-Scale Testing
- Offered with 100 percent sensitivity[i] with samples with a PCR Cycle Threshold (CT) of less than 34, Ortho's test may be better able to identify individuals with COVID-19 who are infectious compared to PCR - Ortho's new SARS-CoV-2 antigen test is the latest addition to the company's COVID-19...
2020-11-05 07:23
1415
Jubilant Radiopharma and SOFIE Biosciences Ink Strategic Partnership Deal to Further Advance the Field of Molecular Imaging & Therapeutics
YARDLEY, Pa., Nov. 4, 2020 /PRNewswire/ -- SOFIE Biosciences, Inc. ("SOFIE"), an established radiopharmaceutical supplier and worldwide radiopharmaceutical contract manufacturing organization, and Jubilant Radiopharma, a business division of Jubilant Pharma Limited, announced that both the organi...
2020-11-04 21:00
1679
Leading Cell Therapy Company JW Therapeutics Lists on Main Board of HKEX
SHANGHAI, Nov. 3, 2020 /PRNewswire/ -- JW Therapeutics (stock code: 2126.HK), a leading clinical stage cell therapy company inChina that focuses on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors, today celebrates...
2020-11-03 10:37
3908
SK Biopharmaceuticals and LifeSci Venture Partners Forge Ties for Open Innovation
SK Biopharmaceuticals aims to promote open innovation and increase global competitiveness through venture capital partnerships PANGYO, GYEONGGI PROVINCE, Korea, Nov. 3, 2020 /PRNewswire/ -- SK Biopharmaceuticals, Co., Ltd., a global innovative pharmaceutical company, announced today the company ...
2020-11-03 00:46
2093
Senhwa Announces Multiple IND application submissions to U.S. FDA for Silmitasertib as a Potential Treatment for COVID-19
TAIPEI and SAN DIEGO, Nov. 2, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc.
(TPEx: 6492), a clinical-stage biopharmaceutical company focused on
next-generation DNA Damage Response (DDR) therapeutics for the treatment of
cancer, today announced that it has submitted an Investigational New Drug
2020-11-02 22:00
1741
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7433
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
6834
